Category: Uncategorized

COMMUNICATE YOUR IDEAS VISUALLY with clean pictorial summaries of complex data and options, including Venn Diagrams, decision trees, and geometric symbols. A pictorial summary can be hugely effective and memorable as a communication tool. View in LinkedIn

FIRST IN CLASS, AND BEST OF BREED are common terms in Biopharma business presentations. The First in Class refers to a novel Mechanism of Action (MOA), and Best of Breed to ranking in a class of the same molecular targets. The first is a disruptive innovation at a molecular level, identifying a novel target, while the second is an incremental improvement on known targets. Both the disruptive and incremental advances can score tremendous valuations, illustrating that disruptive is not the only legitimate goal for entrepreneurs or investors. View in LinkedIn

STARTING YOUR OWN BUSINESS? Read this article on negotiating, because this one activity probably will occupy the bulk of your working time. You will negotiate with your team, your landlord, your vendors, your board, your investors, and do not forget -- your family. Your job is to continually find the middle ground and wisest course between competing options. http://lnkd.in/3CS3ck View in LinkedIn

2012 BIO TRENDS are looking positive overall and it seems that the nuclear winter of the past few years is thawing. Investor optimism will likely continue to be driven by liquidity events through M&As and IPOs. As usual, the US is the leader of these trends, with a lag in Europe, which has a much thinner VC and IPO base. http://lnkd.in/UEsQFb View in LinkedIn

BIOPHARMA IS A FORMIDABLE ECONOMIC ENGINE OF GROWTH. "The biotech industry is a key driver of modern economic progress" (Battell, 2098). Although only about forty years old, by 2015 it is predicted to exceed 320 B USD in sales, and generate well over 1 M skilled well-paying jobs. Considering that the global Pharma industry is driven by only about 370 new drugs approved in the past decade, it is clear that the room for growth is considerable. View in LinkedIn

DUE DILIGENCE IS NEARLY IMPOSSIBLE if a company wishes to hide something, or if there is fraud. Exhaustive checklists, and representations and warranties can be dodged or misrepresented, if you have gone through due diligence and found nothing at all amiss, this should be a red flag. Your final resort is to triangulate with as many sources as possible, and perhaps most importantly, follow your gut feelings. There are more war stories about incomplete due diligence than perhaps any other business topic. Be highly skeptical and don't fall in love with an idea. Always be ready to walk away. View in LinkedIn

IF YOU NEED TO CHANGE YOUR BOARD for the right reasons, not because you are in the wrong job, or want a new fan club, consider the following. First, be honorable and ensure that you have met reasonable expectations about fees and equity. A good board is no more a charity than you are. Secondly, properly thank and acknowledge their contributions. Thirdly, think very hard about how you do it, because the last thing you want to do is insult people who have worked hard for you. Fail to do these three things and you may find it comes up during due diligence by new board members. View in LinkedIn

HOW TO WORK WITH YOUR BOARD. A good board can be invaluable for a growing company. Key rules are: no surprises, no games and politics, timely and good communication, and always listen carefully. All boards have fiscal responsibilities to shareholders, and surprises are universally unpopular. Stuff happens, but be sure to communicate it rapidly and completely. Politics almost always results in a divided and unhappy board. And if you are unable or unwilling to listen to the board, either you are the wrong person or you picked a lousy board. It is your job to make the board relationship work. View in LinkedIn

WESTERN BUSINESS IDEAS ARE NOT NECESSARILY ADAPTED FOR OTHER CULTURES as this article expansively points out. The need for culturally-appropriate solutions is highlighted. The discussion has clear implications if your company wants to do business in Asia, that you cannot ignore large cultural differences. Bottom line: partner with a local company if you want to do sales abroad. http://yourviet.blogspot.com View in LinkedIn

PHARMACEUTICALS face competitive hurdles from numerous sources: the scientific risk in innovation is not trivial; then there is the Regulatory risk, where good drugs fail not because they are bad but due to trial design or lack of statistical power in a study; and finally, even when these two immense hurdles are overcome, agencies like Britain's NICE, or the US equivalent give the thumbs up or down on actually paying for the medicine. http://lnkd.in/2j4hWn View in LinkedIn